Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-402257 for the Treatment of ER⁺/HER2^– Breast Cancer

Treadwell Therapeutics announced that the US FDA has granted Fast Track Designation to CFI-402257 for the treatment of adult patients with ER+/HER2– advanced breast cancer after disease progression on prior CDK4/6 inhibitors and endocrine therapy, both as a monotherapy and in combination with fulvestrant.